LabCorp received emergency use authorization from the FDA for its at-home Covid-19 test kit. CNBC's "Squawk Box" reports.
The actual number of coronavirus cases in the United States is likely significantly higher — as much 10 or even 20 times higher — than the tally of Covid-19 infections currently being reported, a former top federal health official said Tuesday.
“There’s certainly under-diagnosis going on,” Dr. Scott Gottlieb said during an interview with CNBC’s “Squawk Box.”
As of Tuesday, there were more than 787,900 coronavirus cases officially diagnosed in the U.S., with at least 42,364 deaths from the virus.
The actual number of cases “probably is 10 times as many,” said Gottlieb, a former commissioner of the U.S. Food and Drug Administration, and a CNBC contributor.
“We’re probably diagnosing 1 in 10 to 1 in 20 infections, and that’s what some of the reliable analyses are now showing,” he said.
If Gottlieb is correct, that would mean that there are between almost 8 million and 15.75 million Americans who already have contracted the coronavirus, or between 2.4% to 4.8% of the U.S. population.
But it would also mean that the death rate from coronavirus cases could be markedly lower than official reports.
Gottlieb spoke a day after the publication of an analysis of the coronavirus outbreak in Los Angeles County, which estimated that the number of actual cases there is between 28 and 55 times greater than than the number of confirmed cases, which as of Monday was just under 8,000.
The University of Southern California and the Los Angeles Department of Public Health, citing antibody testing of about 863 people, estimated that slightly more than 4% of LA County’s adult population has antibodies to the coronavirus.
The research estimates that there are actually 221,000 adults to 442,000 adults in the county who have been infected.
Gottlieb cautioned Tuesday that the LA analysis, and another study conducted in California, are claiming an ability to accurately detect antibodies that is “higher than any test on the market.”
He said that “small differences in the specificity of the test have a big difference on the reliability of the test ... so I think you need to put those particular valuations in perspective.”
For more coronavirus live updates:
[ Ссылка ]
For access to live and exclusive video from CNBC subscribe to CNBC PRO:
[ Ссылка ]
» Subscribe to CNBC TV: [ Ссылка ]
» Subscribe to CNBC: [ Ссылка ]
» Subscribe to CNBC Classic: [ Ссылка ]
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: [ Ссылка ]
Follow CNBC on LinkedIn: [ Ссылка ]
Follow CNBC News on Facebook: [ Ссылка ]
Follow CNBC News on Twitter: [ Ссылка ]
Follow CNBC News on Instagram: [ Ссылка ]
#CNBC
#CNBC TV
